Abstract
Successful treatment of malignant disease is based on extensive knowledge of the biology of a given tumor and, as a consequence, the prognosis of the disease. At the moment, only a few parameters are known which correlate with the prognosis of renal cell carcinoma (RCC). Several investigators could demonstrate a close correlation between tumor stage and patient survival (Böttiger 1970; Golimbu et al. 1986; Giuliani et al. 1983; Klöppel et al. 1986; Robson et al. 1969). The impact of the tumor grade on the prognosis of the disease is a matter of discussion. While some authors report a good correlation between tumor grade and the course of the disease, this could not be confirmed by others (Donhuijsen 1986; Fuhrman et al. 1982; Klöppel et al. 1986; Kofler et al. 1975; Syrjänen and Hjelt 1978). Recently, the value of biological markers, e.g., DNA content, the expression of differentiation or proliferation antigens and of antigens belonging to the cytoskeleton, has been investigated (Bohle et al. 1986; Fleming and Symes 1987; Fleming and Brown 1987; Ljungberg et al. 1986; Loy et al. 1986).
Supported by the Bundesminister für Forschung und Technologie and the Minister für Wissenschaft und Forschung des Landes Nordrhein-Westfalen, FRG
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bohle B, Waldherr R, Schwechheimer K, Moldenhauer G, Momburg F (1986) Immunhistochemische Charakterisierung von Nierenzellkarzinomen. Verh Dtsch Ges Pathol 70: 274–278
Böttiger LE (1970) Prognosis in renal carcinoma. Cancer 26: 780–787
Donhuijsen K (1986) Nierenzellkarzinome: Prognostische Bedeutung der Zellkerngröße. Verh Dtsch Ges Pathol 70: 634
Falkenberg FW, Ruffelmann HB, Müller E, Gutenberg W, Behrendt B, Waks T (1981) Monoclonal antibodies against antigens in the human kidney. In: Hämmerling GJ, Hämmerling U, Kearney JF (eds) Monoclonal antibodies and T-cell hybridomas. Elsevier/North-Holland, Amsterdam, pp 148–155
Fleming S, Brown G (1987) The expression of 3-fucosylated-iV-acetyl lactosamine carbohydrate determinants in renal tumours. Histopathol 11: 171–182
Fleming S, Symes CE (1987) The distribution of cytokeratin antigens in the kidney and in renal tumours. Histopathol 11: 157–170
Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655–663
Giuliani L, Martorana G, Giberti C, Pescatore D, Magnani C (1983) Results of radical nephrectomy with extensive lymphadenectomy for renal cell carcinoma. J Urol 130: 664–668
Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27: 291–301
Hermanek P (1986) Neue TNM/pTNM-Klassifikation und Stadieneinteilung urologischer Tumorenab 1987. Urologe (B) 26: 193–197
Hermanek P, Sigel A, Chlepas S (1976) Histological grading of renal cell carcinoma. Eur Urol 2: 189–292
Kearny JF, Radbruch A, Liesegang B, Rajewsky K (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123: 1548–1550
Klöppel G, Knöfel WT, Baisch H, Otto U (1986) Prognosis of renal cell carcinoma related to nuclear grade, DNA content and Robson stage. Eur Urol 12: 426–431
Kofler K, Reichl ER, Zischka-Konorsa W (1975) Statistische Untersuchungen zur Frage der Beziehungen zwischen Morphologie und Prognose bei Nierenparenchymcarcinomen. Virchows Arch [A] 368: 347–359
Köhler G, Milstein C (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256: 495–497
Lieber MM, Tornera FM, Taylor WF, Farrow GM (1981) Renal adenocarcinoma in young adults: survival and variables affecting prognosis. J Urol 125: 164–168
Ljungberg B, Forsslund G, Stenling R, Zetterberg A (1986) The prognostic significance of nuclear DNA content in renal cell carcinoma. J Urol 135: 422–426
Loy V, Krech R, Gerdes J, Kramer W, Stein H (1986) Malignitätsgrad und Wachstumsfraktion beim Nierenzellkarzinom. Verh Dtsch Ges Pathol 70: 633
Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301
Schmitz-Dräger BJ, Rohde D, Peschkes C, Ebert T, Ackermann R (1988) Monoklonale Antikörper gegen Harnblasenkarzinome - ein Beitrag zur Verbesserung der Diagnostik? Akt Urol 19: 217–223
Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) The diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 28: 1165–1177
Syijänen K, Hjelt L (1978) Grading of human renal adenocarcinoma. Scand J Urol Nephrol 12: 49–55
Thoenes W, Störkel St, Rumpelt HJ (1985) Pathomorphologische Systematik und Nomenklatur der Nierenzelltumoren (insbesondere Nierenzellkarzinome) der Erwachsenen. Verh Dtsch Ges Pathol 69: 429
Wright WC, Daniels WP, Fogh J (1981) Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis. J Natl Cancer Inst 66: 239–247
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schmitz-Dräger, B.J., Rohde, D., Frenzel, H., Ackermann, R. (1989). Biological Markers in the Evaluation of Prognosis in Patients with Renal Cell Carcinoma. In: Rübben, H., Jocham, D., Jacobi, G.H. (eds) Investigative Urology 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74438-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-74438-9_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74440-2
Online ISBN: 978-3-642-74438-9
eBook Packages: Springer Book Archive